Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

BICO, Audiocast, Q3'26

By Inderes11/11/2026, 9:00 AM
BICO Group

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Anders Fogelberg
00:01 - 14:18

Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa Linsäter. This is my first quarterly report since assuming the CEO role on September 1st. After joining BICO in mid-2024 as Chief Commercial Officer, I have spent a lot of time with our businesses, teams, and customers. Those conversations have reinforced where we are strongest, but also where we need greater focus and discipline. I want to thank our employees, customers, and partners for their candid input, valuable insights, and continued trust in BICO. So before we turn to the third quarter results, I would like to introduce BICO 2030, our new strategy, which we are launching today. Ewa will then cover the quarter, and I will close with our Q4 focus before the Q&A. Let me start with the thinking behind the BICO 2030 Strategy. This is not about changing BICO's purpose or ambition. Our vision remains the same: to enable life science labs to accelerate the discoveries that change lives. BICO 2030 is about being much clearer about where we can compete, where we can create the most value, and where we should allocate our resources. To explain that, let me first take a step back and look at how we got here. BICO 2030 is the result of a three-step process during 2026. In the spring, we carried out a comprehensive, customer-focused business review across all our businesses. Over the summer, it became the basis for updated commercial plans, and this autumn, together with our assessment of the large-scale lab automation project business, it came together in one group strategy. The review confirmed that many of BICO's strongest technologies, scientific capabilities, and customer relationships already sit within what we today define as Precision Biology. We do not need to become a different company. We already have a strong foundation to build from. It also drew on what we learned from executing our previous strategy. And one conclusion stands out. An attractive market and a competitive advantage in that market are not the same thing. We did not deliver on all the ambitions of BICO 2.0, particularly in scaling Biosero into the growth platform envisioned. We underestimated what it takes to scale a large, customized product business built on third-party hardware in a market that became more competitive, capital-intensive, and disrupted by AI. The outcome is a strategy grounded in our portfolio, customer demand and BICO's competitive edge. We are concentrating on our strongest positions. So, where are our strongest positions? In total, we serve three growing markets worth around 10 billion USD. 3D biology and biomaterials are worth 2.7 billion USD and are growing at low double digits. As research shifts from animal tests to human-relevant 3D models, cell imaging, isolation, and cell line development represent a $3.4 billion market growing at high single digits, driven by new modalities such as monoclonal antibodies, cell and gene therapies, and automation. Of the wet lab, $4.1 billion, growing at mid to high single digits. As AI moves the bottleneck from discovery and design to validation in the wet lab, and as labs automate and miniaturize, our current serviceable market within these segments is approximately 1.5 billion USD, growing at an estimated 4 to 7% annually. Behind these markets is a real problem worth solving. Of around 18,500 recognized diseases, only about 4,000 have an FDA-approved treatment, which is about 1 in 5, and drug development remains long, expensive, and complex. Around $300 billion in annual R&D. It takes 10 to 15 years to bring a drug to market and $2.7 billion per approved drug, including failures. At the same time, science is moving quickly. Advanced cell models, automation and AI are changing how researchers identify, test and validate potential new therapies. The challenge is increasingly about generating better biological data earlier and more efficiently. That is the problem Precision Biology addresses and where we believe BICO can make a meaningful difference. BICO comes into play early in discovery and preclinical, the first 3 to 5 years, and about a third of R&D spend. Only 1 in 13 candidates entering clinical trials is approved, and the costliest phases come late, with phase three alone accounting for more than a quarter of R&D spend. At the same time, AI is transforming early drug discovery, accelerating target identification and the design of new molecules. As models generate candidates faster than ever, more of them need to be tested on living material, and that work still happens in the physical lab. This makes the wet lab a critical bottleneck. An AI-designed candidate cannot progress forward toward a therapy until it has been tested and validated in living biology. With that step, much of the speed gained through AI upstream is lost. More reproducible workflows, higher-quality data, and better human-relevant models can help identify weak candidates before late-stage costs and time accumulate. Our precision biology instruments and offerings are built for exactly this work, making them enablers of AI-driven drug discovery. At its core, BICO 2030 is about focus to accelerate Precision Biology. BICO is the precision biology company. Each of our brands brings a specific capability for handling living material precisely: the growth matrix, the conditions, the placement, and the analysis. Our lead market is cell-based applications in biotech and pharma where the need for precision is greatest. That is where we will concentrate our commercial resources, innovation and capital, building on differentiated capabilities and established customer relationships. The success of BICO 2030 will be measured by our ability to translate that focus into sustainable growth, improved profitability, and stronger cash generation. Across our businesses. We have differentiated capabilities in precision biology in three areas: handling, preparing, moving, and placing biological material with products like I.DOT and UP.SIGHT. Culture. Culturing and maintaining the conditions biology needs with BIO X and our 3D matrices and analysis. Turning observations into evidence with CELLCYTE and our Rebel and Revolve microscopes. And these are just a few examples. Automation, AI, and consumables run across all three. Importantly, we do not need to build these from scratch. These capabilities exist in our products today. So how will BICO 2030 translate into value creation? And importantly, how should you expect to see progress over time? This strategy is built around three priorities. First, Precision Biology. At the core, we will concentrate resources on cell solutions and 3D cell models where our competitive advantage is strongest. Large-scale integrated lab automation projects will no longer be a core focus. We are assessing strategic options for Biosero to determine its best long-term path. Importantly, we are not moving away from lab automation itself, but from large, highly customized integration projects built around third-party instruments and third-party automation hardware. The value creation logic is straightforward: accelerate organic sales growth in our high-quality and, in some cases, world-leading instruments, increase the share of consumables, services, and software, and reduce our exposure to large, customized projects that have reduced profitability. Second, customer-driven innovation enabled by AI, R&D will be more closely aligned with customer demand. We will use AI in product development, make instruments ready for software agents and robots, and increasingly incorporate AI into the products themselves, complemented by selective bolt-on acquisitions. This should give us higher returns on R&D, faster development, and software revenue on our installed base. Third, accountability close to the customer. Our business units will own growth, profitability, and execution, supported by a lean group function, driving strong commercial execution and operating leverage. Together, these priorities are how we intend to achieve our financial targets. And that brings me naturally to our financial ambitions. First, three observations. Past performance showed the group has not consistently reached its financial targets. What Biosero taught us is that large-scale automation projects did not provide the leading, scalable platform we envisioned, and this is what the review confirmed. We already have businesses that drive growth and profitability. So, the strategic choice is to focus where BICO has the clearest competitive advantage and the strongest path to profitable growth. BICO 2030 changes where we focus and how we execute, but it does not change our financial ambition. The board has reconfirmed our existing long-term financial targets: double-digit organic growth in constant currencies, an EBITDA margin (less capitalized development costs) of about 10%, and a net debt to EBITDA ratio below three times. New long-term financial targets will be defined once the current targets have been achieved. We are also strengthening our executive management to increase business accountability and bring decision-making closer to our customers. As of today, Ewa and I will be joined by three new members. Julian Riba joins as Chief Technology Officer, bringing deep experience in developing and bringing life science instruments to market with a strong focus on advancing our AI capabilities across products and R&D. Petros Apostolopoulos joins as Managing Director of Lab Instruments, with a particular focus on businesses including the SCIENION, Athena, and Echo, as well as the strategic development of our broader offering. Avijit Minocha joins as Managing Director of SCIENION, bringing extensive commercial and operational experience from across the group. Together, these changes bring business leadership closer to group decision-making and strengthen the connection between customers, commercial priorities, and technology development. At the same time, Katherine Woodland and Jesper Höglund will continue in their current roles and as members of our extended leadership team, but will leave the executive management. Strategy ultimately comes down to execution, and execution depends on culture. For us, that culture will be built around three values. Ownership means clear accountability for our actions, decisions, and results, and following through on our commitments. Innovation means curiosity and the courage to explore new ideas, embracing technology and new ways of working to keep finding better ways forward. And impact means the difference our work makes, helping our customers succeed and contributing to discoveries and therapies that can change lives. Ownership. Innovation. Impact. This is a culture we are building and how we will execute. BICO 2030. Today I have deliberately focused on the high-level strategic direction. On November 25th, we will host a dedicated Strategy Deep Dive, where we will go further into BICO 2030 and how we intend to execute this strategy. You can register at bico.com/investors. Today is also about our Q3 interim report. So, I will now hand over to Ewa Linsäter to take you through our third quarter financial performance.

Ewa Linsäter
14:19 - 22:14

Thank you, Anders. I will now take you through the group's financial performance for the third quarter of 2026. Unless otherwise stated, all figures in this section are in Swedish kronor and refer to continuing operations. Let me begin with a few key figures from the quarter. Net sales came in at 465 million SEK. That is an increase of 20% quarter-over-quarter and 19% organically. Q3 is a strong quarter, but the most important message is not the growth rate. It is that our core bench business continues to grow while our cost base is coming down. Excluding the large-scale integrated automation project, business instrument sales grew 14% and our consumables grew 5%. Adjusted EBITDA was 124 million, giving us an adjusted EBITDA margin of 27%. On working capital, we ended the quarter at 15% of rolling 12 months sales. Cash flow from operating activities was -41 million, mainly due to movements in working capital. Sales grew by 20% and by 19% organically in Q3. SCIENION signed extended supply and license agreements with a diagnostic customer. Prolonging an existing collaboration. The agreement contributed €135 million in revenue during the quarter. On this, €83 million related to license revenue for the five-year non-cancellable period. Recognized at a point in time, the agreements are estimated to have a combined contractual value of approximately €50 million over a ten-year term. Our Q2 report disclosed €3.9 million in revenue related to earlier periods and €10.6 million in total license revenue. Of the €10.6 million, €2.9 million related to earlier periods and was therefore also included in the €3.9 million. While the license income is recognized upfront under IFRS, the cash is received over the contractual term. This creates a timing difference between earnings and cash flow. Excluding the supply and license agreements. Sales declined, with instrument sales down 11% in the quarter. The prior year quarter was unusually strong, reflecting a new large-scale integrated automation project launched during that period with high initial traded third-party instruments. Our own BICO benchtop instruments, however, continued to perform well, with sales up 14%. Consumables sales also grew by 5%. North America remained our most important market and accounted for just over 70%, even if it was boosted this quarter with the revenue related to the SCIENION supply and license agreement. We see improved gross profit, mainly due to the SCIENION agreements, but also excluding this effect, gross profits were stronger compared to the same quarter last year, generated from continued favorable product mix and outsourced production. Turning to our profitability, adjusted EBITDA was 124 million SEK with a margin of 27%. The reported profitability is exceptionally strong and includes a significant contribution from the SCIENION agreements. We therefore do not view the Q3 margin as representative of a normal quarterly run rate. What gives us confidence is the combination of underlying growth in benchtop instruments and an improved cost discipline. Sales and administration expenses were lower than a year ago, reflecting actions taken in previous quarters and our continued focus on cost discipline and operational efficiency. Personnel costs and external services have come down, as both were high cost drivers for the group. After the quarter end, we completed the integration of CELLINK into SCIENION, which is the main part of the initiated restructuring program from Q1, which is expected to generate around 30 million in annual savings before turning to cash flow. I will address the Biosero impairment, which follows from the strategic assessment as outlined earlier. In our Q2 report, we said we were assessing our position in the large-scale integrated lab automation project business. That review is now complete, and its conclusion is clearer and harsher than our earlier commentary suggested. Biosero has not developed as expected. Sales and order intake have declined, and the larger legacy projects proved less profitable than anticipated as they were completed. The market is also changing. AI tools are reshaping laboratory automation, and major players are committing substantial capital and resources to their own robotic hardware to meet the requirements for market leadership. Following the assessment, we recognized an impairment of approximately 296 million against Biosero's remaining goodwill and technology. This is a non-cash charge with no effect on liquidity or covenants. We continue to see value in Biosero and are assessing options to determine its ideal long-term potential. We remain fully committed to its customers throughout this process. Cash flow from operating activities was -41 million, mainly reflecting working capital movements. We saw an increase in operating receivables of 85 million, mainly related to the extended supply and license agreements entered into during the quarter. Revenue from these agreements was recognized at a point in time, while the related cash payments are received over the contract term. At the same time, we saw a decrease in operating liabilities with a negative cash flow impact of almost the same amount. 81 million. This includes -10 million from lower accounts payables and -45 million from the decline in long-term projects. We ended the quarter with cash equivalents of 555 million and a net cash position of 124 million. At quarter end. Net working capital was approximately 15% of rolling 12-month sales. This is the highest working capital in several years and has three main drivers. First, at Biosero, working capital increased as we completed existing large-scale projects while taking on fewer new ones. Second, SCIENION accounts receivable and other receivables increased during the quarter linked to the recorded supply and license agreements. Third, accounts payable declined further, also increasing net working capital. Together, these movements weighed on cash conversion in the quarter. Now over to you, Anders.

Anders Fogelberg
22:17 - 24:12

Let me finish with our priorities for the remainder of the year. With BICO 2030 as our strategic direction, the focus now shifts to execution. First, our strategy deep dive is on November 25th. We will also anchor the strategy internally with a clear commercial and operational priority list for each business unit. We will continue to assess options for Biosero to determine its ideal long-term potential while remaining fully committed to its customers. As Ewa just said, we will strengthen the group's capabilities within AI and ramp up for key product launches in 2027, and throughout this, we will maintain strong discipline on costs, cash generation, and capital allocation. Ultimately, BICO 2030 will not be judged by today's announcements. It will be judged by our ability to deliver stronger commercial performance, improved profitability, and cash generation quarter after quarter. As I mentioned, we will go deeper into BICO 2030 at our Strategy Deep Dive on November 25th. That presentation starts at 9:00 a.m. Central European Time. You can register at bico.com/investors and we hope you will join us. Let me close by coming back to our three corporate values: ownership, innovation, and impact. That is the mindset we are bringing to BICO 2030 and to our vision to enable life science labs to accelerate the discoveries that change lives. And once again, thank you to our employees, customers, and partners for the candid discussions, valuable insights, and continued trust in BICO. The direction is clear. Now it is about execution and delivery. With that, Ewa and I are ready to take your questions.

Operator
24:14 - 24:33

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Maria Karlsson Osipova from Carnegie. Please go ahead.

Maria Karlsson Osipova
24:34 - 25:03

Hi, Anders. Hi, Ewa. Thank you for taking my question. And so, I wanted to start on the instruments. You did highlight in the report and now in the presentation that our instruments are remaining strong year over year, and the comparable quarter last year was exceptionally strong as well. Could you elaborate a bit more on that? And also, what should we expect to see going forward? So maybe talk a little bit about what we see developing into Q4. Thank you.

Anders Fogelberg
25:04 - 26:22

Absolutely. We are very happy with the instrument sales in quarter three. We saw strong momentum. We see some momentum coming back in the academic segment. We see good progress in diagnostics for pharma and biotech, and we believe that the AI revolution happening right now is very well positioned for our instruments. The demand for wet lab services and the capabilities that we have are well positioned. The comparison quarter last year, 2025, in Q3, we had a big project start with Biosero that we also announced in a press release. So we had very strong instrument sales that quarter as a reference, but the Biosero products were traded by third parties. So if we remove the Biosero impact from both quarters. And if you also remove the SCIENION one-time effect and just look at our instruments, 40% was the strong result. We don't give forecasts, but I can say that the purpose of the new strategy is to give us the best conditions possible to consistently reach our financial targets.

Maria Karlsson Osipova
26:25 - 27:01

All right. Thank you. And a little bit more on general market conditions. We have heard generally in the life science industry that there have been gradually improving market conditions, particularly in pharma and biotech. And you mentioned in the report that you continue to see weak academic demand. And then there is some tariff-related pressure and so on. So could you please help us understand the trends a bit more? What do you see out there, and what do you think needs to change in order for you to achieve this double-digit growth target that you have now, or that you had also before?

Anders Fogelberg
27:02 - 28:12

We aim to achieve our financial targets. We launched the new BICO 2030 Strategy, which gives us the best conditions. If you look at the market right now. Yes, we have seen over the last few months that pharma and biotech has been a bit stronger and that diagnostics has done okay as well. We still see the academic segment struggle. I think we mentioned in the last quarter that we see NIH funding returning, but it is favoring bigger projects, which in turn favors more specialized equipment where we are seeing success with some of our assortments. But we also see fewer project starts. Due to the new way that the NIH operates in the US, some of our products that are in the commodity field do not have as strong a market as we saw in the past before the NIH changes started. So the academic segment is still a segment that we follow closely. And it's an important segment for us. But we see some headwind there still.

Maria Karlsson Osipova
28:15 - 28:17

All right. Thank you. I will get back into the queue.

Operator
28:20 - 28:32

As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. The next question comes from Ludvig Lundgren from Arctic. Please go ahead.

Ludvig Lundgren
28:34 - 29:07

Yes. Hi, and thank you for taking my questions. First off, I wanted to start with a follow-up to that last question. So, thinking about point-in-time sales in Q4 last year, which I believe excludes the Biosero business. It was a very strong number in a quite challenging market. So with funding improving now on the pharma and biotech side, how do you view the potential to deliver similar point-in-time sales in Q4 this year?

Anders Fogelberg
29:09 - 29:45

Well, we do not give forecasts at BICO, and we are happy with our Q3 results. We see a strengthening of demand in a few segments that struggled a year ago with the tariffs and the uncertainties, as well as the geopolitical tensions. And we sense when we talk with customers, when we visit events, that things are normalizing a bit. And I think that's what we hear from the other players in this industry regarding Q4. I cannot say anything relating to a future quarter.

Ludvig Lundgren
29:48 - 30:07

Okay. Fair enough. Thanks. And then, just on Q3 here, you had a very significant effect from the license and supply agreement. But is it possible to share the margins, thinking mainly here about the gross margin if adjusting for the effect from this agreement?

Ewa Linsäter
30:09 - 30:31

So we don't give exact numbers, but what we can say and what we said in the call is that if you take out the supply and license agreements, we still see an improved gross profit margin, which comes from product mix, but also from certain outsourcing of instrument production.

Ludvig Lundgren
30:34 - 30:37

Okay. And do you mean an improvement year-over-year, or?

Ewa Linsäter
30:37 - 30:40

Yes, compared to the same quarter last year. Sorry.

Ludvig Lundgren
30:40 - 31:05

Okay. Thanks. And then, I also wanted to ask on the OpEx side, which came in below what I had expected in general. I believe you expect to have the full effect from the cost cutting and restructuring you have done in Q4. But maybe you can elaborate a bit on how much of these effects we are already seeing here in Q3.

Ewa Linsäter
31:07 - 31:38

You can see that we have had improvements during the quarters for this year. We launched the restructuring program in Q1, but we also initiated restructuring in 2025. So we can see that the Q1 restructuring is coming out as expected. So, of course, we see some effects of that in Q3, as we said earlier, and we will see the full effect later in Q4.

Ludvig Lundgren
31:42 - 31:46

Okay, great. Those were my questions. I will jump back into the queue.

Unknown 1
31:47 - 31:47

Thank you.

Operator
31:47 - 31:51

The next question comes from Gustav Meyer at Redeye. Please go ahead.

Gustav Meyer
31:54 - 32:16

Hi, everyone. Thank you for taking my questions as well. Most of my questions have already been answered, but I have just a couple of add-ons. So maybe you talked about the gross margin before, but could you elaborate a bit more on how you expect it to develop now that the mix shifts away from these larger products?

Ewa Linsäter
32:18 - 32:46

So we can see that we have strong growth in benchtop instrument sales. And we have a product mix that is positive in this quarter, in terms of how it looks. We expect the margin to remain at approximately the same level, but we do not provide a forecast for Q4 regarding how we see the gross profit margin evolving.

Gustav Meyer
32:49 - 33:05

Okay. Thank you. Also, you talked a little bit about it in your presentation regarding the R&D priorities. Maybe you could add some more color to that, regarding how the priorities will change with the new strategy.

Anders Fogelberg
33:06 - 34:09

Absolutely. The core of the new strategy is Precision Biology and the products and solutions that support that for our customers. So we are looking at the portfolios of the German instrument companies selling here in Sweden and of course in the US and BICO AB. So what we are looking at is adding functionality to the current portfolio, specifically by integrating AI, which we saw recently with a few of our microscopes and our UP.SIGHT from CYTENA where we are looking at adding AI functionality. We are looking at adding new functions to them. We are also looking, of course, into new next-generation products, hardware, and software. We have some great initiatives going on. We don't talk very openly about exactly what our pipeline of products looks like, but we have initiatives that we strongly believe in that will serve our customers in this new focus area of Precision Biology.

Gustav Meyer
34:12 - 34:16

Perfect. Thank you very much. I will go back to the queue. Thanks.

Operator
34:19 - 34:26

There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Anders Fogelberg
34:28 - 34:40

Thank you all for your questions and for joining us today. We look forward to seeing many of you at our upcoming Strategy Deep Dive later in November. Thank you again and have a great Wednesday.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…